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Abstract: The human digestive system harbors a diverse and complex community of microorganisms
that work in a symbiotic fashion with the host, contributing to metabolism, immune response and
intestinal architecture. However, disruption of a stable and diverse community, termed “dysbiosis”,
has been shown to have a profound impact upon health and disease. Emerging data demonstrate
dysbiosis of the gut microbiota to be linked with non-alcoholic fatty liver disease (NAFLD). Although
the exact mechanism(s) remain unknown, inflammation, damage to the intestinal membrane, and
translocation of bacteria have all been suggested. Lifestyle intervention is undoubtedly effective at
improving NAFLD, however, not all patients respond to these in the same manner. Furthermore,
studies investigating the effects of lifestyle interventions on the gut microbiota in NAFLD patients are
lacking. A deeper understanding of how different aspects of lifestyle (diet/nutrition/exercise) affect
the host–microbiome interaction may allow for a more tailored approach to lifestyle intervention.
With gut microbiota representing a key element of personalized medicine and nutrition, we review
the effects of lifestyle interventions (diet and physical activity/exercise) on gut microbiota and how
this impacts upon NAFLD prognosis.
Keywords: NAFLD; gut microbiota; lifestyle; diet and exercise
1. Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver disease including simple
steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, in the absence of excessive
alcohol consumption [1]. NAFLD is the leading aetiology of liver disease [2], although factors leading to
the development of NAFLD and progression to more advanced liver disease are poorly understood [3].
NAFLD is strongly associated with metabolic syndrome and its features including insulin resistance,
obesity, hyperlipidemia, low high density lipoproteins (HDL), and hypertension and is considered the
hepatic manifestation of the metabolic syndrome [4].
The incidence of NAFLD is closely associated with dietary intake and lack of physical activity,
which typically manifests in obesity [5]. NAFLD is further accompanied by excess risk of type
2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) [6]. The multifactorial aetiology of
NAFLD is determined by both the patient’s genetics and the environmental factors to which they are
exposed, which may account for the substantial inter-patient variability common to the disease [7].
Although genetic polymorphisms have been attributed to account for a small portion of the patient
inter-variability, there are additional contributing factors that have also been identified, spanning
epigenetics, hormones, nutrition and physical inactivity [5,7]. Despite advances in NAFLD pathology,
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the reasons for the large inter-patient variability in progression remains incompletely understood.
Consequently, a potential new diagnostic and therapeutic target receiving considerable attention is the
collection of microorganisms that reside the gastrointestinal (GI) system. Despite humans being >99%
identical genetically, the collection of bacteria, fungi, archea, virus, and phage are hugely diverse and
highly individual from one person to the next. Termed the gut microbiota, bacteria in the gut alone
accounts for around 70% of the total bacteria in the body and include 500–1000 different bacterial
species [8–11].
Bacterial evolutionary linages are represented by phylogenetic trees, demonstrating the
relatedness of bacteria to one another, classified from life, domain, kingdom, phylum, class, order,
family, genus and finally species. The majority of research into gut microbiota has focused on phylum
(Firmicutes, Bacteroidetes, etc.), genus (Bacteroides, Lactobacillus, etc.), and species (Roseburia spp. and
Eubacterium spp.).
2. Gut Microbiota
Historical evidence spanning eight decades has demonstrated a link between the bacteria
in the GI system and the liver, present from early fetal life and throughout life [8,12]. The gut
microbiota in a healthy individual has been shown to be stable, absent of clinical manipulation (e.g.,
antibiotics), provided that a healthy diet and physical activity, combined with a healthy lifestyle (e.g.,
limited alcohol, not smoking, etc.) are maintained [13–18]. A healthy balance of bacteria in the GI
system ensures that the gut microbiota works in a symbiotic nature with the host and its functions
include maintaining a supply of essential nutrients, metabolism, immune response and intestinal
architecture [19]. However, a change in the diversity leading to a reduced abundance of beneficial
bacteria, with increased prevalence of potentially pathogenic bacteria can occur, which has been termed
“dysbiosis” [17]. Dysbiosis of the gut microbiota has been associated with many disease states from
early infancy [20], through childhood [21] and into adulthood [18]. Thus, manipulation of the gut
microbiome to ensure a non-dysbiotic state offers attractive therapeutic for a range of conditions and
overall health status.
Synonymous to NAFLD, inter-patient variability of the gut microbiota is well recognized, with
each individual harboring a unique collection of microorganisms from the thousands that can
potentially colonize, primarily from the phyla Firmicutes, Bacteroides and Actinobacteria [15,22].
Until recently, the majority of research published focused on these phyla, specifically the Firmicutes
and Bacteroides, which are dominant in the gut microbiota from year three of life. However, recent
advances in the throughput and affordability of deoxyribonucleic acid (DNA) sequencing technologies
and associated bioinformatics [23] has facilitated an increased understanding of the pathophysiology
of a number of diseases and adverse health conditions including obesity, metabolic syndrome, diabetes
and cardiovascular disease [18,24–26], all of which are closely associated with NAFLD [4].
3. Gut Microbiota and NAFLD
NAFLD is a complex disease and with advances in the pathology of the disease new
pharmacotherapy treatments are being developed [27,28]. However, lifestyle interventions
accompanied by weight loss of between 5% and 10% remain the cornerstone of treatment [27,29].
The effectiveness of lifestyle changes are unprecedented with improvements in metabolic control and
liver histology, and when accompanied by greater than 10% weight loss NASH resolution, fibrosis
regression and reductions NAFLD activity score [30,31]. However, the difficulty in implementing
and maintaining these lifestyle interventions in clinical practice in NAFLD is well documented, with
randomized long-term studies lacking [32,33].
Due to the intimate relationship between liver and GI tract, it is unsurprising that gut microbiota
dysbiosis has been linked with hepatic fat accumulation, and all stages of NAFLD in both animals
and humans [7,34–41]. Although the exact mechanism linking the gut microbiota with NAFLD
development and progression remains unknown, potential explanations include bacterial overgrowth,
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gut leakiness, increased endotoxemia absorption, and inflammation [3,36,42–45]. The increased
knowledge of the gut microbiota in recent years has enhanced the understanding of the metabolic and
immunological potential and microbial–host interactions, primarily in gut, but also in the liver and
other organs. The role and identity of microbial produced metabolites and their direct function locally
in the gut and also at other body sites remains unknown. However, increasing evidence suggests
the gut microbiota as a genuine target for therapeutic interventions in the management of NAFLD
(Figure 1) [8,19].
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This review provides an overview of gut microbiota and its relationship with NAFLD by reviewing
published data on how diet, nutrition and exercise modulate the gut microbiota and the liver. The
purpose of this review is to assess the impact that lifestyle interventions (excluding pharmaceutical and
surgical) have on gut microbiota and how this may interact with NAFLD development and progression.
4. Lifestyle Interventions in NAFLD
As the incidence of NAFLD increases [1], the individual and societal burden of its management
weigh heavily on health care systems throughout the world, and the need for treatments to co bat
this is crucial [46]. Alt ough the understanding of NAFLD has increased considerably in the last
20 years, the exact cause of why some people develop more severe forms of NAFLD is not fully
understood. The development of NAFLD results from two key factors: (1) greater calories consumed
compared to those expended; and (2) genetic susceptibility. Although genetic susceptibility cannot be
altered (excluding epigenetic changes), calories consumed and expended can be modified, and has
led to a large bo y of research undertaken investigating the impact of various lifestyle modification
interventions [27,29]. Lifestyle interventions that lead to a reduction in weight and/or an increase in
physical activity/exercise have consistently been shown to reduce hepatic lipids, improve glucose
control and insulin sensitivity [29], and more recently improve liver histology [30,31]. The control
of calories consumed vs. those expended may incorporate a number of interventions including
exercise/physical activity independent of weight loss [47–49], diet modification [50–52] or diet and
exercise/physical activity [30,31,53,54]. However, why some patients respond to interventions, and
others do not is unknown. Modulation of the gut microbiota through the various lifestyle modifications
Int. J. Mol. Sci. 2016, 17, 447 4 of 29
discussed here may provide an insight into the inter-patient variability observed in NAFLD, and
improve the number of people who may respond to specific lifestyle interventions to treat NAFLD.
5. Diet and Gut Microbiota
Exposure to environmental factors plays a significant role in the pathophysiology of NAFLD [6],
particular dietary intake [55]. A regular healthy balanced diet has been shown to maintain a stable
and healthy gut microbiota and reduce the risk of numerous diseases [56,57]. Recent evidence
has emphasized the importance of calorie excess, in contrast to macronutrient content, as a major
contributor to weight gain [58]. This is particularly important given the highly calorific content of
the Western diet (high in fat and carbohydrates), which is associated with an altered gut microbiota
and increased risk of developing obesity and NAFLD [35,46,59]. Although there are some conflicting
findings, a strong association has been reported between obesity and changes in the gut microbiota,
which may be responsible for enhanced energy harvest, weight gain and metabolic syndrome [60–62].
The link between the diet and the composition and function of the gut microbiota is unsurprising given
that dietary components provide nutrients for bacteria, which then produce metabolites involved in
energy balance, metabolism, immune response and the pathophysiology of NAFLD [63–65]. Indeed,
bacteria in the gut are responsible for the digestion and production of many essential vitamins and
minerals. The link between diet, gut microbiota, and health has been elegantly shown in animal
models. Animals that were switched from low fat/fiber rich plant diets, to high fat/high sugar
diets had significant increases in Bacilli and Erysipelotrichi from the Firmicutes phylum, which were
associated with a significant decrease in the abundance of members of the Bacteroidetes phylum [66].
Furthermore, the role of the gut microbiome alone in causing obesity, independent of diet, was first
demonstrated by Ley et al. [67] who showed mice transplanted an “obese microbiota” would have
significantly greater weight gain than mice transplanted with a “lean microbiota”. The substantial
impact of the diet has also been shown in humans, where a rural African diet (high in fiber and
vegetables) had a higher relative abundance of Bacteroidetes and a lower relative abundance of
Firmicutes compared with the urban European diet (high in fat and sugar, low in fiber and vegetables).
Even more interesting was that the samples from Africa had two bacterial species (Prevottela and
Xylanibacter) that were not detectable in the European samples. Further evidence has been reported
when comparing a control diet vs. diets high in non-digestible carbohydrates, where the authors
reported that the non-digestible carbohydrates produce significant changes in the composition of the
gut microbiota within a number of days [62].
Although there are contrasting results in the specific bacterial taxa that are modulated through the
diet, the key message is that the diet is able to have a direct and long-term impact on the gut microbiota
composition and function, which has a profound implication for health. Any modulation of the diet,
such as an increase in non-digestible carbohydrates and/or weight loss has the potential to alter the gut
microbiota and potentially disease phenotype, such as NAFLD. This approach of modulating the gut
microbiota by modifying the dietary components (fats, proteins and carbohydrates), probiotics (living
microorganisms that provide health effects on the host), and prebiotics (ingredients that are selectively
fermented and modulate the changes in both the composition and activity of the gut microbiota)
has been established for some time, although the links between specific bacteria with disease and
mechanisms are often lacking [68]. This paper will now report the impact that macronutrients (fats,
proteins and carbohydrates), probiotics and prebiotics manipulation has on the gut microbiota and the
NAFLD phenotype.
6. Fat
Although the exact pathophysiology of NAFLD is unknown, the accumulation of lipids in the
liver is a key pre-requisite for development and progression [69]. The cause of lipid accumulation in the
liver is complex, but has been linked with an influx of fatty acids from fat depots, de-novo lipogenesis,
and excess dietary fat intake, leading to steatosis. Increased fat intake is a common finding in NAFLD
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patients [70,71], thus regulation of fat intake has been highlighted as potential target for therapeutic
intervention to reduce hepatic lipids [72]. Contrasting results have been reported in human studies
that have used a high fat diet to increase hepatic lipid content [73,74], whereas others have reported
no effect of a high fat diet on hepatic lipids [75,76]. The lack of consistency is likely to be due to the
duration of the studies (10 days–3 weeks) and the various forms of fat used (saturated, polyunsaturated
(PUFA) and mono-unsaturated (MUFA)). Furthermore, in a regular Western style diet the high fat
content is normally supplemented by high carbohydrates and therefore it may be the combination of
fat and carbohydrates that stimulate the development and progression of NAFLD [77]. The Western
diet associated with NAFLD has also been associated with gut microbiota dysbiosis, which represents
a potential source for the inter-patient variability observed in NAFLD, and progression from simple
steatosis to NASH [36,78].
Although the exact mechanisms of how high fat diets lead to the development of NAFLD
through gut microbiota modulation are unknown, research has predominantly focused on gut barrier
function [77], leaky gut, endotoxemia, gut derived toxins and inflammation [45,79]. Despite the links
between high fat diets, NAFLD, and the gut microbiota, there is a need to identify specific microbial
changes that may be causative, which would highlight potential targets for diagnosis and treatment.
The majority of studies investigating the impact that a high fat diet can have on the gut microbiota
have been based around changes in the Firmicutes:Bacteroidetes ratio. This was firstly shown by
Turnbaugh, et al. [80] in germ free mice that were fed a high fat diet and failed to develop obesity. Once
inoculated with the microbiota from a mouse fed a high fat diet, the mice had increased weight, hepatic
lipogenesis, fat deposition and insulin resistance, which was associated with an increase in Firmicutes
and a subsequent decrease in Bacteroidetes [80]. This has subsequently been supported by decreases
in Eubacterium rectale, Blautia coccoides, Bifidobacteria sp. and Bacteroides sp. [81–84]. Although these
studies have identified that the gut microbiota is modulated with a high fat diet, the changes reported
are limiting in their specificity (phylum changes rather than species), and the exact mechanism(s)
linking these changes with NAFLD require further investigation.
There have been a number of mechanisms that have been identified to play a role in gut microbiota
dysbiois associated with a high fat diet and the development of NAFLD including gut barrier
dysfunction and translocation of microbes from the gut. Increased endotoxemia and inflammation
in human [85–87] and animal studies [81,88–90] further suggests insulin resistance to be a key to the
development of NAFLD and NASH [90,91]. High fat diets have also been shown to modulate the levels
of Gammaproteobacteria and Erysipelotrichi, which have been shown to lead to choline deficiency,
liver fat accumulation and NASH [65,92–94]. In addition, the ability of high fat diets to alter the gut
microbiota and subsequently bile acids metabolism and synthesis by alleviating farnesoid X receptor
(FXR) [95–97]. Although not exhaustive, the mechanisms discussed here have all been shown to have
a direct impact upon the liver, therefore modulation of the gut microbiota in the presence of a high fat
diet may offer the potential to reduce the risk and development of NAFLD.
The obvious treatment may be to put NAFLD patients on a low fat diet which have been shown
to be effective in weight loss, reduce liver fat, improve metabolic control and modulate the gut
microbiota [10,30,98]. However, managing and maintaining such diets can be difficult [32,33]. A
number of alternative options for patients who may struggle with converting to a low fat diet include
changing the form of fat consumed and increasing non-digestible carbohydrates. MUFA, PUFA
and n-3 PUFA have been incorporated into dietary studies and shown to restore aspects of the high
fat gut microbiota dysbiosis, including changes in Clostridia, Enterobacteriales, Bifidobacterium and
Lactobacillus casei (Table 1) [99,100]. Although these studies do not report how these changes link
with NAFLD, potential explanations may include reduced gut leakiness and inflammation, although
these were not confirmed. In human studies, increases in MUFA, PUFA and n-3 PUFA have been
shown to reduce hepatic lipid content and improve metabolic control in NAFLD patients [73,100],
potentially due to increase fatty acid oxidation, redistribution of fatty acids and down regulation of
gene expression of sterol regulatory element binding protein 1 (SREBP1-c) and factor for apoptosis
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(FAS). It is important to emphasize that the changes reported here did not influence weight, therefore
suggesting the changes in the gut microbiota and hepatic lipids are diet driven rather than weight loss.
The use of non-digestible carbohydrates has been researched for a number of years and shown to
be an effective treatment for increasing satiety, reducing blood glucose, insulin resistance, fat digestion
and inducing weight loss [101]. Furthermore, non-digestible carbohydrates are effective in modulating
gut microbiota and maintaining a healthy GI system [64]. However, the impact upon the gut microbiota
in the presence of a high fat diet and mediators of NAFLD are lacking. Arabinoxylan and chitin-glucan
have been shown to be effective at modulating the gut microbiota by increasing Bifidobacteria and
restoring the abundance of Bacteroides-Prevotella spp., Roseburia spp., and Clostridium cluster fourteen a
(XIVa) that were reduced following a high fat diet (Table 1). These changes in the gut microbiota were
also supported by reductions in body fat, hepatic lipids, serum and hepatic cholesterol and insulin
resistance, independent of calories consumed [102,103]. There is also evidence that, in the presence
of high fat diets, chitosan and arabinoxylan are able to increase fat, bile acids and cholesterol in the
feces. These studies suggest that non-digestible carbohydrates are able to modulate the gut microbiota,
even in the presence of a high fat diet, potentially by binding to fat/cholesterol or inhibiting pancreatic
lipase [101,104,105].
Table 1. Significant bacterial changes following dietary manipulation in the presence of high fat intake.
XIV; fourteen, Ò and Ó denote increase or decrease in variable, respectively.
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Polyunsaturated fatty acids Cells Inhibit growth of mucus Ò Lactobacillus casei [99]
Oleic acid and n-3 fatty
acids (EPA and DHA) Mice
Ó Body Weight Ò Clostridial cluster XIV [100]
Ò Enterobacteriales
Ò Firmicutes
Ó Bifidobacterium
Arabinoxylans Mice
Improved gut barrier function Ò Prevotella spp. [102]
Ó Circulating inflammatory markers Ò Roseburia spp.
Ó Adipocyte size Ò Bifidobacterium
Ó Body weight gain
Ó Serum cholesterol
Ó Hepatic cholesterol
Ó Insulin resistance
Chitin-Glucan Mice
Ó Body weight gain Ò Clostridial cluster XIV [103]
Ó Fat Mass
Ó Fasting Glucose
Ó Hepatic Lipids
Ó Cholesterol
Although a low fat diet may be preferable for patients with NAFLD, such a considerable change
from an established lifestyle will be difficult for patients with NAFLD to incorporate. It is also
important to recognize that, in general, a reduction in fat intake is typically accompanied by an increase
in carbohydrate content. The data here suggest that changing the type of fat ingested and incorporating
a larger proportion of non-digestible carbohydrates into the diet may be effective modulating the gut
microbiota, reducing hepatic lipids and ameliorating risk factors associated with NAFLD. However,
further work is required to assess the impact of diet on the gut microbiota specifically and further
human intervention studies in patients with NAFLD are required to assess this.
7. Carbohydrates
Carbohydrates provide a crucial energy source for the host and gut microbiota [25]. Carbohydrate
fermentation, specifically non-digestible carbohydrates, is a core activity of the human gut microbiota,
driving the energy and carbon economy of the colon [106]. The move towards the Western style diet,
which is high in processed carbohydrates and low in non-digestible carbohydrates, has been attributed
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to the rise and prevalence of obesity and NAFLD in these demographics [8,65,107]. This was recently
confirmed in a meta-analysis where fructose was linked with poor liver health, although this was
confounded by excessive energy intake, which is likely to be due to high fructose intake [108].
Excessive intake of calories in NAFLD is associated with sugar intake, with fructose being
identified as having a crucial role to play (potentially due to altered hormone release). With
regard to NAFLD, excess fructose, which is primarily metabolized in the liver, is linked to elevated
steatosis [109–111]. Fructose has also been suggested to be a key driver in alteration of gut microbiota,
potentially causing dysbiosis, as well as increased intestinal permeability and endotoxins in portal
blood [112,113]. Notably, such factors have been previously reported in NAFLD [114]. Increased
endotoxins and inflammatory cytokines have been identified to be part of the multiple hits hypothesis
that exposes the liver to inflammation and injury [91]. Furthermore, endotoxemia is also linked
with activation of Kupffer cells through toll like receptor dependent mechanisms, weight gain,
poor metabolic control and increased plasma triglycerides, hepatic lipogenic enzymes and hepatic
steatosis [111,113,115–118].
Replacing non-digestible carbohydrates with simple carbohydrates, such as fructose, will alter
the substrate made available to the gut microbiota and ultimately affect the metabolic outputs and
the microbial composition [67,106,119]. Numerous studies have reported that reducing non-digestible
carbohydrates in the diet significantly reduces the levels of Roseburia spp. and Eubacterium rectale
subgroup of cluster XIVa from the Firmicutes phylum and bifidobacteria from the Actinobacteria
phylum [98,120]. More recently, the same group have also shown that increasing the levels of
non-digestible carbohydrates can increase levels of Ruminococcus bromii (phylum:Firmicutes), however,
these changes were dependent on the individuals initial microbiota profile [62]. These changes
reflect the impact that non-digestible carbohydrates have on gut microbiota and subsequent health
implications, although studies linking carbohydrates intake, such as non-digestible carbohydrates and
fructose, with specific bacterial changes in NAFLD are lacking.
There are few studies investigating the effects of high carbohydrate intake similar to the Western
diet on the gut microbiota composition. Ferrere, et al. [121] reported increased relative abundance
of the class Erysipelotrichi (phylum:Firmicutes) following high fructose diet. Turnbaugh, Backhed,
Fulton and Gordon [84] also reported that a high carbohydrate diet was able to increase the relative
abundance of bacteria from the class Mollicutes (phylum:Firmicutes) and enrich genes that encode
fructose metabolism, but reduce genes required for starch and sucrose metabolism. The authors
suggested that the increase in Mollicutes might reduce microbial diversity, including a reduction in
the relative abundance of the genus Bacteroides (phylum:Bacteroidetes), which is associated with poor
health [61]. However, in humans Boursier, Mueller, Barret, Machado, Fizanne, Araujo-Perez, Guy,
Seed, Rawls, David, Hunault, Oberti, Cales and Diehl [7] reported increased levels of Bacteroides in
NASH patients compared to controls, which suggests that the data which we extrapolate from animal
models require validation in human populations. Further studies should ascertain the effect of high
fructose diets on specific bacteria to potentially identify targets for treatment.
The cornerstone of NAFLD treatment is weight loss, through diet and/or physical
activity/exercise, which is effective in improving both liver histology [30] and modulating the gut
microbiota [10,31]. In recent years a reduction in calories in the form of carbohydrates has been
prevalent in many fad diets. Although initially effective for weight loss, such diets also have a
substantial impact upon the gut microbiota and short chain fatty acids (SCFA) [98]. SCFA contribute
around 10% of our daily energy requirements and provide a hospitable environment for cross
feeding between microbial communities [108]. Specifically, a reduction in butyrate and butyrate
producing bacteria has been shown in such diets, which may have detrimental effects on the GI
structure and immune response [98,106,120]. An alternative would be to increase the amount of
non-digestible carbohydrates consumed, which has been shown to be effective in maintaining a
healthy gut microbiota [67] and ameliorating obesity and insulin resistance, which appear to be
necessary for the development of NAFLD [122,123]. Furthermore, SCFA, including butyrate have
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been shown to contribute towards maintaining epithelial integrity, gut motility, hormone secretion,
reducing appetite and inflammation [106], all of which are associated with NAFLD [122,123]. Increased
intake of non-digestible carbohydrates has also been shown to improve glucose uptake, adipokine
profile, and alter colonic fermentation, although the latter was only confirmed with breath tests [124].
Oligofructose specifically has also been shown to induce weight loss, reduce calories consumed and
improved glucose uptake [125]. The authors also reported reductions in grehlin and increased peptide
YY response, which have both been associated with changes in the gut microbiota following dietary
intervention [126,127].
Further treatments to combat the detrimental effects of a high carbohydrate diet may involve
increased protein intake, Vitamin E, and cinnamon [128–131]. All of which have been shown to be
effective in reducing weight gain, body fat, adipocyte size, insulin resistance and hepatic steatosis.
Although these all show promise, there are currently no data on whether these may be able to
modulate the gut microbiota in NAFLD patients and should be explored further. Increased intake of
carbohydrates, specifically fructose, is undoubtedly linked with NAFLD, due to either metabolism in
the liver or through increasing calories consumed. Replacement of these simple carbohydrates with
non-digestible carbohydrates provides potential to have a direct impact upon gut microbiota dysbiosis
and have a positive effect on mediators of NAFLD.
8. Protein
Like carbohydrate, an increase in protein in the diet at the expense of carbohydrates and fat had
been utilized in a number of fad diets to facilitate weight loss [132]. However, the effect that protein
may have on the gut microbiota in humans, and specifically NAFLD are lacking. Furthermore, the
small number of studies investigating the effects of high protein diets have predominantly focused
on the products produced during fermentation [64]. This is surprising given the amount of protein
that reaches the colon in a healthy diet (12–18 g), which would be expected to rise in a high protein
diet [133], and provide nutrients for bacterial proliferation. Although an essential macronutrient,
excess protein has been linked with potentially damaging effects on the gut microbiota and intestinal
structure through toxic substances produced [64,133–135]. The small number of studies that have
reported the impact that high protein diets have on the gut microbiota have reported high levels of
Clostridium spp. and Bacteroides spp., with concurrent reductions in Bifidobacterium spp., Roseburia spp.,
and Eubacterium spp. [136,137]. The reductions in Bifidobacterium spp., Roseburia spp., and Eubacterium
spp. bacterial species are associated with butyrate production, endotoxemia, mucus barrier function,
and insulin sensitivity [81,136]. This suggests that the decreases in these bacteria may be detrimental
to health and increase the risk of NAFLD [35–37,40,138,139].
Various animal models have been used to investigate the impact of protein on the gut microbiome
with the main findings summarized in Table 2. In cats the authors utilized a high protein/low
carbohydrate and a moderate protein and carbohydrate diet for eight weeks [140]. Ordination analysis
of this data demonstrated that increases in the abundance of genre Clostridium, Faecalibacterium,
Ruminococcus, Blautia and Eubacterium were clustered with plasma triglycerides. Contrastingly, piglets
fed a high protein diet showed little microbial change, except reductions in Faecalibacterium prausnitzii,
but were shown to have a higher increase in colonic permeability and higher cytokine secretion [141].
Whether this small change in bacteria can be directly attributed to the bacterial changes remains to
be seen. However, the differing animal models and protein sources may account for the difference
reported here. Further animal data from chickens and rats fed diets high in protein showed reductions
in hepatic lipids and adipose tissue [142–144]. More recently, high protein diets have been shown
to be effective for reducing hepatic lipids, blood lipids, body fat, CVD risk and improve insulin
sensitivity and anti-oxidative potential [132,145–149]. Potential explanations for these results have
been linked with increased satiety, increased energy expenditure, reduced hepatic lipid oxidation,
cell death, hormone release in the GI system and bile acid metabolism [126,127,150], all of which are
associated with the pathophysiology of NAFLD [123].
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Table 2. Significant bacterial changes following high protein intake (Ò and Ó denote increase or decrease
in variable, respectively).
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
High Protein/Moderate
Carbohydrates High Protein/Low
Carbohydrates
Obese
Men
Ò Branch chain amino acids Ó Roseburia [137]
Ò Phenylacetic acid Ó Eubacterium
Ò N-nitroso compounds
Ó Butyrate
Ó Phenolic acids
High Protein/Low Carbohydrates Kittens
Ò Clostridium [140]
Ò Faecalibacterium
Ò Ruminococcus
Ò Blautia
Ò Eubacterium
High Protein Piglets
Ò Branch chain amino acids Ó Faecalibacterium prausnitzii [141]
Ò Colonic Permeability
Ò Cytokine Secretion
Although there has been no direct link between the gut microbiota, NAFLD, and a high protein
diet, there is evidence that an excess of 36 g/day of protein was identified as a risk factor for increasing
the risk of NAFLD [111]. Furthermore, in T2DM an increase in protein intake resulted in reduced
insulin sensitivity, increased gluconeogenesis and increase glucagon [151,152].
Overall, there are contrasting evidence on whether diets high in protein may be an effective
treatment for gut microbiota modulation and NAFLD management. Discrepancies are likely due
to differing study designs, including the source of protein (animal vs. plant protein), varying
manipulations of the diets (protein to carbohydrate and fat ratios) populations sampled (Healthy,
NAFLD, T2DM, obese, etc.) and study duration. The optimal benefits of diets high in protein to
modulate the gut microbiota and aid with NAFLD management strategies should be explored further.
9. Prebiotics and Probiotics
Given the connection between the gut microbiota, diet, and health [65,84], coupled to issues with
sustained dietary modification, an alternative approach utilizes pre- and probiotics to indirectly or
directly confer beneficial colonizers of the GI, respectively [153]. Although there are various definitions,
prebiotics is most commonly referred to as ingredients that are selectively fermented and modulate the
changes in both the composition and activity of the gut microbiota [68,154]. Probiotics are different in
that they are living (viable) microorganisms which have the ability to provide health effects on the
host when provided in adequate amounts, similar to the bacteria that are already present [155].
10. Prebiotics
Fructans are the most extensively studied prebiotics and have been linked with modulation of the
gut microbiota (summarized in Table 3), resulting in positive health benefits. In animal models, the
administration of prebiotics increased 18 potentially beneficial species, notably Bifidobacterium spp.
(Phylum: Actinobacteria) and Bacteroidetes [156–158]. Changes in gut microbiota are also associated
with appetite regulation, improved glucose tolerance, increased satiety, reduced ghrelin, plasma
triglycerides, oxidative stress and inflammation and calories consumed [82,158–160].
Further animal data have demonstrated that prebiotics are able to reduce hepatic lipids,
cholesterol, plasma triglycerides and increase the SCFA propionate [161–163]. Daubioul, Rousseau,
Demeure, Gallez, Taper, Declerck and Delzenne [161] suggested that the improved lipid profile and
hepatic lipids were due to changes in the gut microbiota, which ultimately altered metabolites of
fermentation. Alterations in the acetate:propionate ratio has been shown to reduce lipogenesis and
account for the reductions in hepatic lipids. Although the authors suggest that the changes in SCFA
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are due to modulation of the gut microbiota, the authors failed to measure specific bacteria, focusing
rather on the metabolites. It is intriguing that increased SCFA production, specifically butyrate and
propionate, protect against diet-induced obesity in mice [164]. However, such studies underscore the
need to understand the complex interplay between microbial–host interaction in gut and to which
extent the bacterial community is causing the phenotypes observed.
In human cohorts, where systematic study is challenging, studies elucidating the exact effects
and mechanisms of prebiotics on the gut microbiota and resulting microbial–host interaction are
lacking. Studies in healthy and T2DM patients have provided similar results, reporting increased
satiety and reduced ghrelin, body weight, glucose, and inflammation [125,157,165,166]. There is a
need for studies investigating the effects of prebiotics in NAFLD. In a small pilot study in biopsy
confirmed NASH patients, Daubioul, et al. [167] reported that prebiotics had a positive impact on liver
aminotransferases and insulin, but no effects on plasma triglycerides. A recent study reported that
prebiotics were effective at significantly reducing inflammatory cytokines, liver aminotransferases,
insulin sensitivity and steatosis in NASH patients [168]. Notably, the study compares lifestyle alone
with lifestyle and prebiotics, thus it is difficult to ascertain how much affect the prebiotics with no other
lifestyle interventions alone would have. As with existing animal data, such studies lack analysis of the
gut microbiota and thus relating potential mechanisms to changes in the gut microbiota is not possible.
A recent meta-analysis analyzing 26 randomized controlled trials concluded that prebiotics were
effective in increasing satiety and improving insulin sensitivity [169]. While specific effects of prebiotics
on the gut microbiota remain poorly understood, the majority of studies have reported increases in
Bifidobacteria [170–173]. Dewulf, et al. [174] also reported an increase in Bifidobacteria, as well as
increased levels of Faecalibacterium prausnitzii and reductions in Bacteroides intestinalis, Bacteroides
vulgatus and Propionibacterium, which they associated with endotoxemia, although they failed to report
any changes in plasma endotoxemia. Although these studies demonstrate promise that prebiotics may
be used as a potential treatment for NAFLD, further work is required to investigate additional overall
changes in the gut microbiome. Rapid advances in NGS and other ‘omic technologies offer promise for
more systematic understanding of entire treatment mechanisms. In addition, there are currently no
studies that have reported the effects of prebiotics on hepatic lipids or liver histology, and evidence
linking specific bacteria with the pathophysiology of NAFLD is lacking.
Table 3. Significant bacterial changes following prebiotic consumption (Ò and Ó denote increase or
decrease in variable, respectively).
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Prebiotic Diet Mice
Improved Glucose Tolerance Ó Firmicutes [162]
Improved Leptin Sensitivity Ò Bacteroidetes
Ò GLP-1 Changed 102 taxa
Ò L-cell GLP-1
Ó Fat Mass
Ó Oxidative Stress
Ó Inflammation
Prebiotics—Xylo-oligosaccharide
and inulin
Human
Ò Butyrate Ò Bifidobacterium [164]
Ò Propionate
Ó Acetate
Ó P-creso
Ó Lipopolysaccharides
Prebiotics—β2-1 Fructans Human Ò Bifidobacterium [172]
Prebiotic—Galactooligosaccharides
(GOSs) Human
Ò Phagocytosis Ò Bifidobacterium [173]
Ò Natural killer cells
Ó Inflammation
Prebiotic—Galactooligosaccharides
(GOSs) Human
Ó Inflammation Ò Bifidobacterium [174]
Ó IgA
Ó Calcoprotectin
Ó Cholesterol
Ó Insulin
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Table 3. Cont.
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Prebiotics—Inulin type fructans Human
Ó Fat Mass Ò Bifidobacterium [175]
Ó Plasma Lactate Ò Faecalibacterium prausnitzi
Ó Phosphatidylcholine Ó Bacteroides intestinalis
Ó Bacteroides vulgatus
Ó Propionibacterium
11. Probiotics
Probiotics have been suggested as a potential treatment for patients with NAFLD, due to
their apparent ability to modulate the gut microbiota (Table 4) and impact upon metabolic control,
inflammation, lipid profile and intestinal permeability [155,175], and have been systematically
reviewed in detail elsewhere [176]. However, the exact mechanisms of how probiotics are able to
do this are not fully understood. Although not exhaustive, proposed mechanisms include direct
microbe-to-microbe interaction and competition with pathogenic bacteria potentially leading to
eradication and a healthy balance of gut microbiota [62,177]. Furthermore, probiotics have been
shown to be effective at improving epithelial barrier integrity [178] and stimulating the host immune
response [179,180].
One of the first studies to investigate the use of probiotics was conducted over 10 years ago
in mice. The authors demonstrated that a course of a common brand of probiotics called VSL#3,
which included Streptococcus thermophiles, Lactobacillus (species: acidophilus, delbrueckii, casei and
plantarum) and Bifidobacterium (species: breve, longum and infantis) over four weeks was as effective
as an anti-TNF antibody at improving liver histology, reducing hepatic lipids, and reducing serum
alanine aminotransferase [181]. Importantly, the authors also reported a reduction in pro-inflammatory
cytokines and hepatic insulin resistance resulting from modulation of the gut microbiota, although
they failed to assess this. This early study into probiotics demonstrates potential for ameliorating
multiple hits that are associated with the pathophysiology and development of NAFLD [69,91].
Subsequent to this pioneering study, further animal work has reported that probiotics are effective
at reducing cholesterol, low density lipoproteins (LDL), very low density lipoproteins (VLDL),
triglycerides [182,183], fat depots [184], hepatic lipid content [185–187], steatotic and peroxidase
factors and liver aminotransferase [188,189]. There is also evidence demonstrating improvements in
hepatic insulin resistance and metabolic control [81,186,190,191]
There is also a body of evidence that has reported reduced inflammation and endotoxemia
following probiotic administration period. An exaggerated and damaging inflammatory response
occurs in a range of conditions and current evidence associates dysbiosis of the gut microbiota
with inflammation, although it is unclear if this is cause or effect. This is especially prevalent
in the case of the mucosa and tight protein junctions, where pathogenic bacteria cause damage
and increase gut permeability leading to chronic inflammation and endotoxemia [155,192]. Direct
modulation of the gut microbiota with viable organisms in probiotics has been shown to reduce hepatic
inflammation [188], circulating inflammatory markers [181,191,193], endotoxemia in portal blood [194]
and provide essential nutrients for maintaining intestinal epithelium integrity [178,195].
Although these data do imply that probiotics may play a role in the therapeutic
management of NAFLD, human data are lacking. In obese children who were non-compliant
to lifestyle interventions, probiotics significantly reduced alanine aminotransferase (ALT) and
anti-peptidoglycan-polysaccharide antibodies, but did not reduce liver fat [196]. In three well-designed
randomized controlled studies, the authors observed that probiotics high in Lactobacillus gasseri reduced
abdominal adiposity and serum lipids [197–199]. However, the duration of these studies was relatively
short and the effects on liver steatosis and specific bacterial changes were not reported.
Similar results have been shown in patients with liver disease, where probiotics have been
shown to be effective at restoring neutrophil phagocytic capacity in cirrhosis and reducing IL-10,
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IL-6 and TNF-α secretion and toll like receptor expression [200,201]. More specifically, in NAFLD,
the administration of probiotics resulted in a significant reduction liver aminotransferase [202,203],
although no changes in hepatic lipids, liver histology or gut microbiota were reported.
The majority of the studies discussed suggest that gut microbiota modulation following
consumption of probiotics was responsible for the beneficial effects observed. Early animal data
from Cani, Neyrinck, Fava, Knauf, Burcelin, Tuohy, Gibson and Delzenne [81] demonstrated that
supplementing mice on a high fat diet with Bifidobacterium restored the levels of Bifidobacterium
comparable to controls on a normal chow fed diet. More recently Bifidobacteria added to animal
feed has been shown to increase the abundance of Bifidobacterium and Clostridiaceae and reduce the
abundance of Enterobacteria and Eubacteriaceae [184,187,191,193,204]. The changes in bacterial diversity
discussed here were also supported by reductions in inflammatory cytokines, endotoxemia, hepatic
lipids and gut permeability.
Table 4. Significant bacterial changes following probiotic consumption (Ò and Ó denote increase or
decrease in variable, respectively).
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Probiotic—oligofructose and
Bifidobacterium species Mice
Ó Endotoxemia Ò Bifidobacterium [81]
Improved glucose tolerance
Probiotic—Bifidobacterium longum Rat
Ó Endotoxemia Ò Bifidobacterium [185]
Ó Inflammation
Ó Intestinal myeloperoxidase
Ó Body Weight
Ó Fat Depots
Ó Systolic Blood Pressure
Improve insulin sensitivity
Probiotic—Bifidobacterium longum
or Lactobacillus acidophilus Rat
Ó Hepatic Lipids Ò Bifidobacterium longum [188]
Ò Lactobacillus acidophilus
Probiotic—Bifidobacterium
pseudocatenulatum Mice
Ó Cholesterol Ò Bifidobacterium [192]
Ó Triglycerides Ó Enterobacteria
Ó Glucose levels
Ó Insulin resistance
Ó Leptin
Ó Inflammation
Ó Hepatic Lipids
Probiotic—Bifidobacterium
pseudocatenulatum Mice
Ó Inflammation Ó Firmicutes [194]
Ó Endotoxemia Ó Proteobacteria
Ó B cells
Ó Macrophages
Ó Cholesterol
Ó Body Weight Gain
Ó Triglycerides
Ó Insulin resistance
Probiotic—Bifidobacterium breve Mice
Ò Propionate Ò Clostridiaceae [205]
Ó Eubacteriaceae
Although existing data suggest probiotics represent a safe and effective treatment option for
NAFLD, there are instances where probiotics were ineffective, such as in Crohn’s disease [205] and
Helicobacter infections [206]. Such results may simply represent inefficiency of the probiotics selected
for these studies and it is plausible different probiotic combinations may yield different results. It
should be noted that probiotics are regarded as safe, with little data showing any adverse effects
of supplementation. As each disease is uniquely complex, so too must the probiotic selected for
treatment, with better characterization of the disease mechanism informing the specific probiotics to
use [62]. Important considerations also include the route of administration, dosage, how often to take
the treatment, and for how long. As we better understand the most effective means of administering
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probiotics as well as which specific combinations of bacteria to use, the efficacy of treatment should
become apparent. In the era of personalized medicine it is feasible that each NAFLD patient can have
their gut microbiota profile determined, allowing probiotics to be tailored to the individual.
12. Exercise
Exercise is well recognized for its health benefits and its ability to attenuate the risk of CVD, obesity,
mental disorders, diabetes and intestinal diseases [207,208]. More specifically exercise has been shown
to be effective at modulating hepatic steatosis and its mediators, improve body composition, liver and
adipose tissue insulin sensitivity independent of weight loss [29,47–49,209]. Furthermore exercise (both
endurance and high intensity) training has been shown to attenuate inflammation and improve insulin
secretion by upregulating glucagon-like peptide-1 secretion in the GI tract and pancreas [209–211].
Despite the strong associations among exercise, liver health, metabolic control and inflammation,
evidence linking exercise, the gut microbiota and NAFLD in humans is lacking. Understanding the
interplay between the triad and resulting mechanisms in NAFLD will be fundamental to translating
therapeutics into clinical practice.
In a recent study, Clarke, et al. [212] investigated the effects of effects of exercise in rugby players
compared sedentary overweight and obese controls. The authors observed that the highly active rugby
players had a significantly more diverse gut microbiota and lower levels of inflammatory and metabolic
markers compared to the controls. Specifically, the authors identified increased relative abundance
of Firmicutes, Proteobacteria and reduced relative abundance of Bacteroidetes. These observations
are based on extremities of a population with vastly different diet and calorie consumption, thus
linking findings directly to the gut microbiota is challenging [18,213]. The authors acknowledge these
confounding variables, stating future studies must be well designed in an attempt to isolate the effects
that exercise may have on the gut microbiota.
Although animal models do not offer a direct comparison with humans, the control over
interventions allows an excellent model to develop disease states and may make it easier to tease out the
impact that exercise alone may have on the gut microbiota. To date, there are no animal studies looking
specifically at exercise and the gut microbiota in an animal model of NAFLD. There are, however, a
number of other animal studies that have investigated the effects of exercise on the gut microbiota in
type 2 diabetes [214], obesity, CVD [215], high fat intake [216,217] and low activity levels [218], which
are all risk factors for the development and progression of NAFLD [5,6], summarized in Table 5.
Table 5. Significant bacterial changes following exercise (Ò and Ó denote increase or decrease in
variable, respectively).
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Controlled treadmill
running Mice
Ò Lactobacillus spp. [215]
Ò Clostridium leptum (C-IV)
Ó Clostridium cluster (C-XI)
Ó Bifidobacterium spp
Controlled treadmill
running Rat
Ó Blood Lactate Ò Allocaculum [216]
Ò Pseudomonas
Ò Lactobacillus
Ó Streptococcus
Ó Aggregatibacter
Ó Sutturella
Voluntary wheel
running Mice
Ó Body Weight Ò Bacteroidetes [217]
Ó Body Fat Ó Firmicutes
Ó Blood glucose Ó Actinobacteria
Ò Heart:Body Weight
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Table 5. Cont.
Intervention/Treatment ModelUsed Non-Microbiome Changes Bacterial Changes Reference
Controlled wheel
running Mice
Ó Streptococcus [218]
Ó Bacteroidetes
Ò Firmicutes
Voluntary wheel
running Rat
Ó Body Fat Ó Firmicutes [219]
Ò Lean Body Mass Ò Cyanobacteria
Ó Non-esterified fatty acids Ò Proteobacteia
Ó Cholesterol
Voluntary wheel
running Rat
Ò Cecal size and weight Ò SM7/11 [220]
Ò Butyrate production Ò T2-87
Ó Body Weight
Voluntary and forced
treadmill running Mice
Ó Body Weight Ò Dorea [221]
Ò Anaerotruncus
Ò Nautilia
Ò Coprococcus
Ò Oscillospira
Ó Turicibacter
Ó Moryella
Ó Prevotella
Voluntary wheel
running Mice
Ó Body Weight Ò Enterococcsceae [222]
Ò Staphylococcsceae
Ó Erysipelotrichaceae
Voluntary wheel
running Rat
Ò Body Weight Ò B. Coccoides-E Rectale [223]
Ò Serum Leptin Ò Lactobacillus
Ó Serum Ghrelin Ó Clostridium
Ó Enteroccocus
Ó Prevotella
Ó Bacteroides
Voluntary wheel
running Rat
Ò Body Weight Ó Rikenellaceae g_AF12 [224]
Ò Lean Body Mass Ó Rikenellaceae g
Ó Desulfovibrio spp
Ò Blautia spp
Ò Turicibacter
Ò Anaerostipes spp
Ò Methanosphaera
Single Peak Exercise
Test
Human
Ò Bacteria in blood Ò Actinobacteria [225]
Ò Firmicutes
The first animal study to investigate the effects of exercise on the gut microbiota was performed
nearly a decade ago using rats who voluntarily exercised for five weeks [219]. Rats that exercised had
a distinctly different bacterial cluster from the sedentary rats, with a significant increase in bacterial
producing bacterium (SM7/11 and T2-87). The exercised mice also consumed fewer calories, had
reduced body weight and an in increase in butyrate. Both voluntary and forced exercise has since been
shown to elicit significant clustering and increased richness of the gut microbiota, with distinctive
changes in the abundance of genus Lactobacillus, Bifidobacterium, Dorea, Turicibacter, Anaerotruncus and
species Enterococcus faecium when compared with sedentary animals [220–222].
The role of genetic and epigenetic predisposition is unclear, but the gut microbiota evolves
with the host from birth [8,12]. Therefore, early manipulation of the microbiota may have beneficial
effects later in life. Genetically altered rats with low activity levels from birth had a greater shift
in bacterial diversity when compare to the highly active rats [218]. Furthermore, this extenuated
increase in bacterial diversity in the low activity rats was supported by a greater improvement in body
composition and serum lipid profile, when compared with the highly active mice. The beneficial effects
of exercise early in life suggests that even in those with a genetic predisposition to be sedentary may
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be able to modulate their gut microbiota and risk factors for NAFLD. Further evidence was presented
when exercising juvenile and adults rats [223]. Juvenile rats had greater shifts in bacterial composition
when compared with the exercising adult rats, which were closely related to body composition of the
rats. These studies together suggest that early stimulus and the activity predisposition (low vs. high)
may be involved in characterizing gut microbiota phenotypes.
Further exercise studies have investigated the effects of exercise on the gut microbiota in
hypertension, obesity and diabetes, which are all closely associated with NAFLD [6]. Petriz, Castro,
Almeida, Gomes, Fernandes, Kruger, Pereira and Franco [215] exercised obese and hypertensive
rats five times per week for four weeks and observed altered composition and diversity of the
gut microbiota, with specific increases in Allobaculum in hypertensive rats, and Pseudomonas and
Lactobacillus in the obese rats. In a similar exercise intervention, Lambert, Myslicki, Bomhof, Belke,
Shearer and Reimer [214] exercised diabetic and control mice and compared them with matched
sedentary controls. The authors observed a significant increase in the abundance of several Firmicutes
species and reductions in the abundance of Bacteroides spp., which had previously been reported
in humans [212]. The only human study to look at the acute effects of exercise on gut microbiota
was performed in patients with myalgic encephalomyelitis/chronic fatigue syndrome compared
to healthy controls [224]. The authors reported that following a single maximal exercise bout the
gut microbiota of patients was significantly altered in comparison with controls. Furthermore the
patients had a significantly larger level of bacteria recovered in the blood when compared with the
healthy controls. Although the authors only conducted a single bout of exercise, they suggest that the
altered gut microbiota led to an increase in bacterial translocation and may contribute to worsening
myalgic encephalomyelitis/chronic fatigue syndrome. The increased bacteria in the blood may be
due to an increase in inflammatory cytokines (IL-6, IL-8, IL-1β, and TNF-α), which have been shown
to be required to initiate villus injury and reduce intestinal barrier function [210]. However, the
authors failed to report on inflammation, and it must be pointed out that the exercise performed was
maximal, which would not be routinely performed. Despite this there is a large body of evidence
demonstrating that exercise is able to reduce inflammation [211], hepatic lipids [29], and improves
metabolic control [47,209,225,226]. However, further work would need to compare different modalities
of exercise and intensities to assess their impact on the gut microbiota, liver fat, metabolic control,
inflammation and patients health.
Inter-study variability has been reported by Petriz, Castro, Almeida, Gomes, Fernandes, Kruger,
Pereira and Franco [215], who reported increased relative abundance of Allobaculum, Pseudomonas and
Lactobacillus. However, Liu, Park, Holscher, Padilla, Scroggins, Welly, Britton, Koch, Vieira-Potter and
Swanson [218] reported increased relative abundance of Christensenellaceae, Helicobacteraceae and
Desulfovibrionaccae, and Choi, Eum, Rampersaud, Daunert, Abreu and Toborek [221] reported
increased relative abundance of the family Enterococcaceae and decreased relative abundance
of Erysipelotrichaceae.
Possible reasons for discrepancy reported between studies may include; varying disease type and
status amongst studies, exercise intervention duration and/or intensity, diet incorporated (ranging
from high fat diet to regular animal chow) and body composition changes. Of particular note, the
varying methods and technologies used to extract and sequence the 16S rRNA gene creates potential
sources of bias between studies.
Exercise does appear to be able to modulate the gut microbiota and reduce the risk of NAFLD,
however, the mechanism(s) remain unknown. Potential mechanisms include: (1) increased butyrate
production, which is linked with colonic epithelial cell proliferation and modulation of mucosal
immunity and exclusion of pathogens [215,219,227]; (2) increased primary bile acid secretion and
cholesterol turnover [228]; (3) growth of beneficial bacteria [221]; and (4) increased core body
temperature and reduced blood flow to the GI system reducing gut transit time and substrate delivery
to the microbiota [218,229,230]. Although the exact mechanism remains elusive and methodological
bias hinders direct cross-study comparisons, existing data indicate that exercise may be able to
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modulate the composition, diversity and relative abundance of the gut microbiota in NAFLD patients.
Further investigation of the impact of exercise on gut microbiota is required and may address why
some patients respond to exercise and some do not.
13. Conclusions
The gut microbiota has been studied for decades, however, recent developments in 16S rRNA
gene sequencing, coupled to advances in computational processing of data has enhanced our
understanding of the microbial–host interactions [23]. The gut microbiota has been associated with a
range of diseases, from obesity, metabolic syndrome, diabetes, and cardiovascular disease [18,24–26]
to NAFLD [7,34,36–41]. However, existing studies are largely focused on profiling the bacterial
community and fail to provide functional information between the gut microbiota and the host.
Ultimately, it still remains unknown whether the gut microbiome is causing the disease, or simply an
effect of disease pathophysiology.
This review reveals that diet, pre/probiotics, and exercise play a significant role in the function
and diversity of the gut microflora. To date, studies have predominantly focused on pre-clinical
models, which have limitations in the transferability of their data to humans. Although much is
known, significant questions about how lifestyle therapies may influence the gut microbiota as a
therapeutic target for NAFLD care. However, the links between the gut microbiota and NAFLD should
continue to be explored to:
(1) better understand inter-patient variability;
(2) develop potential biomarkers for NAFLD development and progression;
(3) understand the mechanism(s) linking the gut microbiota and NAFLD;
(4) develop an understanding of how aspects of lifestyle interventions interact with the gut
microbiota and how this may impact upon health; and
(5) tailor prebiotics and probiotics to influence health for each individual.
Furthermore, although these lifestyle interventions clearly impact upon NAFLD, understanding
of how they interact with the gut microbiota and NAFLD is lacking and requires longitudinal studies
with large sample sizes. For example, the diet has been shown to modulate the gut microbiota in
days [62], but these changes are generally reversed in a similar time frame. Therefore, we need
to understand the best mechanisms for modulating the long-term establishment of a healthy gut
microbiota and the resulting health implications this may have.
As technologies are increasingly developed and the associated costs are reduced, there is huge
potential to systematically determine the importance of both the presence of certain bacteria and their
ultimate function is a given community. For understanding such complex processes and interaction
at the microbe and host levels, there is a need to integrate multiple techniques in a systems biology
approach. A focus on large-scale collaborative studies that explore many relevant biological samples
to comprehensively determine disease mechanisms and therapeutic efficiency is necessary. This
represents an important time for life sciences and the prospect of advances in diseases such as NAFLD
is promising.
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